CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
Unusual Whales
The fifth individual administered with CER-1236, who did not show improvement with previous treatments, received a stem cell transplant. The company has commenced the third intended group in the continuous Phase 1 trial for hematologic malignancies.
